Home › Autoimmune Diseases › NCT01733082
The Mycophenolate Pregnancy Registry
Who can join
All ages · Women
Full eligibility criteria
Inclusion Criteria: * Pregnancy and reported maternal exposure to mycophenolate during pregnancy or within 6 weeks of discontinuing treatment Exclusion Criteria: * Pregnancies for which there is paternal exposure only * Pregnancies occurring outside the U.S.
About the study
The Mycophenolate Pregnancy Registry is designed as a prospective, observational registry collecting data regarding mycophenolate exposure during pregnancy, and pregnancy outcomes, fetal and infant outcomes after exposure. Early and later term pregnancy outcomes will be solicited at selected gestational time points. Structural and functional birth defects identified in the perinatal period through one year of life will be collected and classified.
This is a non-proprietary registry and is a component of a comprehensive pregnancy Risk Evaluation and Mitigation Strategy (REMS) plan required by the FDA for all mycophenolate-formulations, including CellCept, Myfortic and any generic formulations.
Sponsor: Genentech, Inc. · Participants: 500 · Started: Nov 20, 2012
Contact the study team
- Reference Study ID Number: ML22679 https://forpatients.roche.com/ No attachments to email below. · Phone: 888-662-6728 (U.S. and Canada)
Official record on ClinicalTrials.gov — NCT01733082
Locations in the U.S.
| Massachusetts | Quintiles Outcome, Cambridge |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.